APO Research
Talk to an analyst

APO RESEARCH · REPORT

Varicella Live Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Varicella Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025194 pages

Choose your research edition.

Industry ResearchVaricella Live Vaccine Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Live Vaccine Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Varicella Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Live Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Live Vaccine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Varicella Live Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Varicella Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Varicella Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Varicella Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Varicella Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Varicella Live Vaccine include Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Sanofi Pasteur, Panacea Biotec, Mitsubishi Tanabe Pharma Corporation and MedImmune, LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Varicella Live Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Varicella Live Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Varicella Live Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Varicella Live Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Varicella Live Vaccine Segment by Company

Johnson & Johnson

Merck & Co., Inc.

Pfizer, Inc.

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

Sanofi Pasteur

Panacea Biotec

Mitsubishi Tanabe Pharma Corporation

MedImmune, LLC

Emergent BioSolutions, Inc.

Daiichi Sankyo

CSL Limited

Biological E

Bavarian Nordic

Astellas Pharma Inc.

Varicella Live Vaccine Segment by Type

Monovalent Vaccines

Multivalent Vaccines

Varicella Live Vaccine Segment by Application

Herpes Zoster Immunization

Measles Immunization

Chicken Pox Immunization

Others

Varicella Live Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Live Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Live Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Varicella Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Varicella Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Varicella Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Varicella Live Vaccine Industry Trends Table 2. Varicella Live Vaccine Industry Drivers Table 3. Varicella Live Vaccine Industry Opportunities and Challenges Table 4. Varicella Live Vaccine Industry Restraints Table 5. Global Varicella Live Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Varicella Live Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Varicella Live Vaccine Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Varicella Live Vaccine Sales Market Share by Manufacturers Table 9. Global Varicella Live Vaccine Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Varicella Live Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Varicella Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Varicella Live Vaccine Manufacturers, Product Type & Application Table 13. Global Varicella Live Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Varicella Live Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Monovalent Vaccines Table 17. Major Manufacturers of Multivalent Vaccines Table 18. Global Varicella Live Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Varicella Live Vaccine Sales by Type (2021-2026) & (k units) Table 20. Global Varicella Live Vaccine Sales by Type (2027-2032) & (k units) Table 21. Global Varicella Live Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Varicella Live Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Varicella Live Vaccine Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Varicella Live Vaccine Revenue by Type (2021-2026) & (k units) Table 25. Global Varicella Live Vaccine Revenue by Type (2027-2032) & (k units) Table 26. Global Varicella Live Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Varicella Live Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Herpes Zoster Immunization Table 29. Major Manufacturers of Measles Immunization Table 30. Major Manufacturers of Chicken Pox Immunization Table 31. Major Manufacturers of Others Table 32. Global Varicella Live Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Varicella Live Vaccine Sales by Application (2021-2026) & (k units) Table 34. Global Varicella Live Vaccine Sales by Application (2027-2032) & (k units) Table 35. Global Varicella Live Vaccine Sales Market Share by Application (2021-2026) Table 36. Global Varicella Live Vaccine Sales Market Share by Application (2027-2032) Table 37. Global Varicella Live Vaccine Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Varicella Live Vaccine Revenue by Application (2021-2026) & (k units) Table 39. Global Varicella Live Vaccine Revenue by Application (2027-2032) & (k units) Table 40. Global Varicella Live Vaccine Revenue Market Share by Application (2021-2026) Table 41. Global Varicella Live Vaccine Revenue Market Share by Application (2027-2032) Table 42. Global Varicella Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Varicella Live Vaccine Sales by Region (2021-2026) & (k units) Table 44. Global Varicella Live Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Varicella Live Vaccine Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Varicella Live Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Varicella Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Varicella Live Vaccine Sales by Country (2021-2026) & (k units) Table 49. North America Varicella Live Vaccine Sales by Country (2027-2032) & (k units) Table 50. Europe Varicella Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Varicella Live Vaccine Sales by Country (2021-2026) & (k units) Table 52. Europe Varicella Live Vaccine Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Varicella Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Varicella Live Vaccine Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Varicella Live Vaccine Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Varicella Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Varicella Live Vaccine Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Varicella Live Vaccine Sales by Country (2027-2032) & (k units) Table 59. Global Varicella Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Varicella Live Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Varicella Live Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Varicella Live Vaccine Revenue Market Share by Region (2021-2026) Table 63. Global Varicella Live Vaccine Revenue Market Share by Region (2027-2032) Table 64. Johnson & Johnson Company Information Table 65. Johnson & Johnson Business Overview Table 66. Johnson & Johnson Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Johnson & Johnson Varicella Live Vaccine Product Portfolio Table 68. Johnson & Johnson Recent Development Table 69. Merck & Co., Inc. Company Information Table 70. Merck & Co., Inc. Business Overview Table 71. Merck & Co., Inc. Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Merck & Co., Inc. Varicella Live Vaccine Product Portfolio Table 73. Merck & Co., Inc. Recent Development Table 74. Pfizer, Inc. Company Information Table 75. Pfizer, Inc. Business Overview Table 76. Pfizer, Inc. Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer, Inc. Varicella Live Vaccine Product Portfolio Table 78. Pfizer, Inc. Recent Development Table 79. GlaxoSmithKline plc Company Information Table 80. GlaxoSmithKline plc Business Overview Table 81. GlaxoSmithKline plc Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline plc Varicella Live Vaccine Product Portfolio Table 83. GlaxoSmithKline plc Recent Development Table 84. Serum Institute of India Pvt. Ltd. Company Information Table 85. Serum Institute of India Pvt. Ltd. Business Overview Table 86. Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product Portfolio Table 88. Serum Institute of India Pvt. Ltd. Recent Development Table 89. Sanofi Pasteur Company Information Table 90. Sanofi Pasteur Business Overview Table 91. Sanofi Pasteur Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sanofi Pasteur Varicella Live Vaccine Product Portfolio Table 93. Sanofi Pasteur Recent Development Table 94. Panacea Biotec Company Information Table 95. Panacea Biotec Business Overview Table 96. Panacea Biotec Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Panacea Biotec Varicella Live Vaccine Product Portfolio Table 98. Panacea Biotec Recent Development Table 99. Mitsubishi Tanabe Pharma Corporation Company Information Table 100. Mitsubishi Tanabe Pharma Corporation Business Overview Table 101. Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product Portfolio Table 103. Mitsubishi Tanabe Pharma Corporation Recent Development Table 104. MedImmune, LLC Company Information Table 105. MedImmune, LLC Business Overview Table 106. MedImmune, LLC Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. MedImmune, LLC Varicella Live Vaccine Product Portfolio Table 108. MedImmune, LLC Recent Development Table 109. Emergent BioSolutions, Inc. Company Information Table 110. Emergent BioSolutions, Inc. Business Overview Table 111. Emergent BioSolutions, Inc. Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Emergent BioSolutions, Inc. Varicella Live Vaccine Product Portfolio Table 113. Emergent BioSolutions, Inc. Recent Development Table 114. Daiichi Sankyo Company Information Table 115. Daiichi Sankyo Business Overview Table 116. Daiichi Sankyo Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Daiichi Sankyo Varicella Live Vaccine Product Portfolio Table 118. Daiichi Sankyo Recent Development Table 119. CSL Limited Company Information Table 120. CSL Limited Business Overview Table 121. CSL Limited Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. CSL Limited Varicella Live Vaccine Product Portfolio Table 123. CSL Limited Recent Development Table 124. Biological E Company Information Table 125. Biological E Business Overview Table 126. Biological E Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Biological E Varicella Live Vaccine Product Portfolio Table 128. Biological E Recent Development Table 129. Bavarian Nordic Company Information Table 130. Bavarian Nordic Business Overview Table 131. Bavarian Nordic Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Bavarian Nordic Varicella Live Vaccine Product Portfolio Table 133. Bavarian Nordic Recent Development Table 134. Astellas Pharma Inc. Company Information Table 135. Astellas Pharma Inc. Business Overview Table 136. Astellas Pharma Inc. Varicella Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Astellas Pharma Inc. Varicella Live Vaccine Product Portfolio Table 138. Astellas Pharma Inc. Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Varicella Live Vaccine Distributors List Table 142. Varicella Live Vaccine Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Varicella Live Vaccine Product Image Figure 2. Global Varicella Live Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Live Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Varicella Live Vaccine Sales (2021-2032) & (k units) Figure 5. Global Varicella Live Vaccine Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Varicella Live Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Monovalent Vaccines Image Figure 9. Multivalent Vaccines Image Figure 10. Global Varicella Live Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Varicella Live Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Varicella Live Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Varicella Live Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Varicella Live Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Varicella Live Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Herpes Zoster Immunization Image Figure 17. Measles Immunization Image Figure 18. Chicken Pox Immunization Image Figure 19. Others Image Figure 20. Global Varicella Live Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Varicella Live Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Varicella Live Vaccine Sales Market Share by Application (2021-2032) Figure 23. Global Varicella Live Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Varicella Live Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Varicella Live Vaccine Revenue Market Share by Application (2021-2032) Figure 26. North America Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Varicella Live Vaccine Sales Market Share by Country (2021-2032) Figure 28. U.S. Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Varicella Live Vaccine Sales Market Share by Country (2021-2032) Figure 33. Germany Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Varicella Live Vaccine Sales Market Share by Country (2021-2032) Figure 40. China Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Varicella Live Vaccine Sales Market Share by Country (2021-2032) Figure 48. Brazil Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Varicella Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Varicella Live Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Varicella Live Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Varicella Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. North America Varicella Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Varicella Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Europe Varicella Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Varicella Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Varicella Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Varicella Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Varicella Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Varicella Live Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Varicella Live Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Monovalent Vaccines
  • Multivalent Vaccines
Applications
  • Herpes Zoster Immunization
  • Measles Immunization
  • Chicken Pox Immunization
  • Others
Companies covered
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Sanofi Pasteur
  • Panacea Biotec
  • Mitsubishi Tanabe Pharma Corporation
  • MedImmune, LLC
  • Emergent BioSolutions, Inc.
  • Daiichi Sankyo
  • CSL Limited
  • Biological E
  • Bavarian Nordic
  • Astellas Pharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Varicella Live Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Varicella Live Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Varicella Live Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Varicella Live Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Varicella Live Vaccine Market Dynamics
  1. 2.1 Varicella Live Vaccine Industry Trends
  2. 2.2 Varicella Live Vaccine Industry Drivers
  3. 2.3 Varicella Live Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Live Vaccine Industry Restraints
3 Varicella Live Vaccine Market by Manufacturers
  1. 3.1 Global Varicella Live Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Varicella Live Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Varicella Live Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Varicella Live Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Varicella Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Varicella Live Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Varicella Live Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Varicella Live Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Varicella Live Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Varicella Live Vaccine Tier 1, Tier 2, and Tier 3
4 Varicella Live Vaccine Market by Type
  1. 4.1 Varicella Live Vaccine Type Introduction
  2. 4.1.1 Monovalent Vaccines
  3. 4.1.2 Multivalent Vaccines
  4. 4.2 Global Varicella Live Vaccine Sales by Type
  5. 4.2.1 Global Varicella Live Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Varicella Live Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Varicella Live Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Varicella Live Vaccine Revenue by Type
  9. 4.3.1 Global Varicella Live Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Varicella Live Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Varicella Live Vaccine Revenue Market Share by Type (2021-2032)
5 Varicella Live Vaccine Market by Application
  1. 5.1 Varicella Live Vaccine Application Introduction
  2. 5.1.1 Herpes Zoster Immunization
  3. 5.1.2 Measles Immunization
  4. 5.1.3 Chicken Pox Immunization
  5. 5.1.4 Others
  6. 5.2 Global Varicella Live Vaccine Sales by Application
  7. 5.2.1 Global Varicella Live Vaccine Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Varicella Live Vaccine Sales by Application (2021-2032)
  9. 5.2.3 Global Varicella Live Vaccine Sales Market Share by Application (2021-2032)
  10. 5.3 Global Varicella Live Vaccine Revenue by Application
  11. 5.3.1 Global Varicella Live Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Varicella Live Vaccine Revenue by Application (2021-2032)
  13. 5.3.3 Global Varicella Live Vaccine Revenue Market Share by Application (2021-2032)
6 Global Varicella Live Vaccine Sales by Region
  1. 6.1 Global Varicella Live Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Varicella Live Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Varicella Live Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Varicella Live Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Varicella Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Varicella Live Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Varicella Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Varicella Live Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Varicella Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Varicella Live Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Varicella Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Varicella Live Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Varicella Live Vaccine Revenue by Region
  1. 7.1 Global Varicella Live Vaccine Revenue by Region
  2. 7.1.1 Global Varicella Live Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Varicella Live Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Varicella Live Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Varicella Live Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Varicella Live Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Varicella Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Varicella Live Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Varicella Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Varicella Live Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Varicella Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Varicella Live Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Varicella Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Varicella Live Vaccine Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Varicella Live Vaccine Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Pfizer, Inc.
  14. 8.3.1 Pfizer, Inc. Company Information
  15. 8.3.2 Pfizer, Inc. Business Overview
  16. 8.3.3 Pfizer, Inc. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer, Inc. Varicella Live Vaccine Product Portfolio
  18. 8.3.5 Pfizer, Inc. Recent Developments
  19. 8.4 GlaxoSmithKline plc
  20. 8.4.1 GlaxoSmithKline plc Company Information
  21. 8.4.2 GlaxoSmithKline plc Business Overview
  22. 8.4.3 GlaxoSmithKline plc Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline plc Varicella Live Vaccine Product Portfolio
  24. 8.4.5 GlaxoSmithKline plc Recent Developments
  25. 8.5 Serum Institute of India Pvt. Ltd.
  26. 8.5.1 Serum Institute of India Pvt. Ltd. Company Information
  27. 8.5.2 Serum Institute of India Pvt. Ltd. Business Overview
  28. 8.5.3 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product Portfolio
  30. 8.5.5 Serum Institute of India Pvt. Ltd. Recent Developments
  31. 8.6 Sanofi Pasteur
  32. 8.6.1 Sanofi Pasteur Company Information
  33. 8.6.2 Sanofi Pasteur Business Overview
  34. 8.6.3 Sanofi Pasteur Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur Varicella Live Vaccine Product Portfolio
  36. 8.6.5 Sanofi Pasteur Recent Developments
  37. 8.7 Panacea Biotec
  38. 8.7.1 Panacea Biotec Company Information
  39. 8.7.2 Panacea Biotec Business Overview
  40. 8.7.3 Panacea Biotec Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Panacea Biotec Varicella Live Vaccine Product Portfolio
  42. 8.7.5 Panacea Biotec Recent Developments
  43. 8.8 Mitsubishi Tanabe Pharma Corporation
  44. 8.8.1 Mitsubishi Tanabe Pharma Corporation Company Information
  45. 8.8.2 Mitsubishi Tanabe Pharma Corporation Business Overview
  46. 8.8.3 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product Portfolio
  48. 8.8.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
  49. 8.9 MedImmune, LLC
  50. 8.9.1 MedImmune, LLC Company Information
  51. 8.9.2 MedImmune, LLC Business Overview
  52. 8.9.3 MedImmune, LLC Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 MedImmune, LLC Varicella Live Vaccine Product Portfolio
  54. 8.9.5 MedImmune, LLC Recent Developments
  55. 8.10 Emergent BioSolutions, Inc.
  56. 8.10.1 Emergent BioSolutions, Inc. Company Information
  57. 8.10.2 Emergent BioSolutions, Inc. Business Overview
  58. 8.10.3 Emergent BioSolutions, Inc. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Emergent BioSolutions, Inc. Varicella Live Vaccine Product Portfolio
  60. 8.10.5 Emergent BioSolutions, Inc. Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Varicella Live Vaccine Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 CSL Limited
  68. 8.12.1 CSL Limited Company Information
  69. 8.12.2 CSL Limited Business Overview
  70. 8.12.3 CSL Limited Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CSL Limited Varicella Live Vaccine Product Portfolio
  72. 8.12.5 CSL Limited Recent Developments
  73. 8.13 Biological E
  74. 8.13.1 Biological E Company Information
  75. 8.13.2 Biological E Business Overview
  76. 8.13.3 Biological E Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Biological E Varicella Live Vaccine Product Portfolio
  78. 8.13.5 Biological E Recent Developments
  79. 8.14 Bavarian Nordic
  80. 8.14.1 Bavarian Nordic Company Information
  81. 8.14.2 Bavarian Nordic Business Overview
  82. 8.14.3 Bavarian Nordic Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bavarian Nordic Varicella Live Vaccine Product Portfolio
  84. 8.14.5 Bavarian Nordic Recent Developments
  85. 8.15 Astellas Pharma Inc.
  86. 8.15.1 Astellas Pharma Inc. Company Information
  87. 8.15.2 Astellas Pharma Inc. Business Overview
  88. 8.15.3 Astellas Pharma Inc. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Pharma Inc. Varicella Live Vaccine Product Portfolio
  90. 8.15.5 Astellas Pharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Varicella Live Vaccine Value Chain Analysis
  2. 9.1.1 Varicella Live Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Varicella Live Vaccine Production Mode & Process
  6. 9.2 Varicella Live Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Varicella Live Vaccine Distributors
  9. 9.2.3 Varicella Live Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst